SH
Seraxis Holdings, Inc.
StreetZero Signal 76
About Seraxis Holdings, Inc.
Seraxis, Inc. is a biotechnology company founded in 2013 and based in Germantown, Maryland. It develops cell-based therapies for diabetes, with its lead program SR-02 focused on pancreatic islet replacement therapy using novel pancreas-derived stem cells for patients with insulin-requiring diabetes. The company has completed preclinical studies of pancreatic organoids and expanded its leadership team. It has entered a merger agreement with Sernova Corp. to form BetaNova Biotherapeutics.
LATEST FUNDINGPrivate Placement
$10.0M
Announced 2026-09-24
TOTAL RAISED$50M
IN THE NEWS
- 🔗 Seraxis Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 Seraxis - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Seraxis announces closing of second VC tranche and successful completion of preclinical studies of pancreatic organoids from Seraxis’ novel pancreas-derived stem cells - T1D Fund: A Breakthrough T1D Venture
- 🔗 Seraxis Employee Directory, Headcount & Staff | LeadIQ
EMPLOYEES11-50
FOUNDED2013
HQGermantown, MD, United States
Industry
Biotechnology
Tags
BiotechnologyCell TherapyDiabetes
Key highlights
- Raised total funding of $50M over five rounds with latest Series C in 2023.
- Developing SR-02 islet replacement therapy from pancreas-derived stem cells.
- Entered merger with Sernova to form BetaNova Biotherapeutics focused on cell replacement for diabetes.
- Secured $10M convertible note financing from existing shareholders to advance toward 2027 clinical trials.
- Completed preclinical studies and expanded leadership with a Chief Corporate Development Officer.
Ask StreetZero about Seraxis Holdings, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account